These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23548688)

  • 1. In vitro activity of doripenem plus fosfomycin against drug-resistant clinical blood isolates.
    Lingscheid T; Tobudic S; Poeppl W; Mitteregger D; Burgmann H
    Pharmacology; 2013; 91(3-4):214-8. PubMed ID: 23548688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM; Aranza MK; Shah D; Sahm DF
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem.
    Ueda Y; Kanazawa K; Eguchi K; Takemoto K; Eriguchi Y; Sunagawa M
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4185-96. PubMed ID: 16189097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus.
    Yu XH; Song XJ; Cai Y; Liang BB; Lin DF; Wang R
    J Antibiot (Tokyo); 2010 Nov; 63(11):657-9. PubMed ID: 20877368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
    Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
    Fritsche TR; Stilwell MG; Jones RN
    Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of S-(3,4-dichlorobenzyl)isothiourea hydrochloride and novel structurally related compounds against multidrug-resistant bacteria, including Pseudomonas aeruginosa and Burkholderia cepacia complex.
    Nicholson A; Perry JD; James AL; Stanforth SP; Carnell S; Wilkinson K; Anjam Khan CM; De Soyza A; Gould FK
    Int J Antimicrob Agents; 2012 Jan; 39(1):27-32. PubMed ID: 21993484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
    Garrison MW; Mutters R; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
    Kiratisin P; Keel RA; Nicolau DP
    Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
    Balode A; Punda-Polić V; Dowzicky MJ
    Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of multidrug-resistant organisms recovered at a military burn center.
    Keen EF; Robinson BJ; Hospenthal DR; Aldous WK; Wolf SE; Chung KK; Murray CK
    Burns; 2010 Sep; 36(6):819-25. PubMed ID: 20080354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae.
    Clock SA; Tabibi S; Alba L; Kubin CJ; Whittier S; Saiman L
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):343-6. PubMed ID: 23601454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
    Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.
    Walkty A; Adam HJ; Laverdière M; Karlowsky JA; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):348-55. PubMed ID: 21353964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergy of fosfomycin with beta-lactam antibiotics against staphylococci and aerobic gram-negative bacilli.
    Chin NX; Neu NM; Neu HC
    Drugs Exp Clin Res; 1986; 12(12):943-7. PubMed ID: 3569007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
    Dong SX; Wang JT; Chang SC
    J Microbiol Immunol Infect; 2012 Dec; 45(6):459-64. PubMed ID: 23102796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of resistance to fluoroquinolones among gram positive and gram negative clinical isolates.
    Nesar S; Shoaib MH; Rahim N; Rehman R
    Pak J Pharm Sci; 2012 Oct; 25(4):877-81. PubMed ID: 23010009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.